Hematology Strategic Roundup | June 8–July 10, 2026
Key Strategic Developments and Competitive Shifts in Hematology Coverage: June…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: Galecto acquires Damora Therapeutics
Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional…
Lucid Diligence Brief: Electra Therapeutics $183M Series C
Lucid Diligence Brief: Electra Therapeutics $183M Series C Professional…
Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025)
This week’s hematology update highlights groundbreaking CAR-T and gene therapy…